XOMA Royalty Concludes Acquisition of LAVA Therapeutics
In a landmark move, XOMA Royalty Corporation (Nasdaq: XOMA) has announced the completion of its acquisition of LAVA Therapeutics N.V. (NASDAQ: LVTX). This acquisition involved the purchase of all outstanding common shares of LAVA, valued at €0.12 each, with shareholders receiving $1.04 in cash for each share as well as a non-transferrable contingent value right (CVR) associated with the shares.
Transaction Highlights and Financial Considerations
Shareholders of LAVA Therapeutics stand to benefit from a variety of financial incentives as part of this transaction. Each shareholder received not only immediate cash but also a CVR, affording them a share in potential future proceeds related to LAVA’s partnered assets and other programs. Specifically, these rights entitle shareholders to receive 75% of net proceeds from certain business developments, as well as the possibility of additional payments based on a final assessment of certain liabilities.
XOMA’s Strategic Vision
Owen Hughes, the Chief Executive Officer of XOMA Royalty, emphasizes the strategic significance of this acquisition by stating, "The acquisition of LAVA Therapeutics reinforces XOMA’s philosophy of ‘strength in numbers’." He expressed optimism regarding the possibilities this collaboration creates, especially given LAVA’s innovative early-stage bispecific antibodies developed in partnership with pharmaceutical giants like Johnson & Johnson and Pfizer.
Acquisition Details and Corporate Reorganization
The offer period concluded recently, with a remarkable tender of approximately 91.1% of the shares validly accepted. Consequently, LAVA's corporate structure underwent a reorganization that allowed XOMA Royalty to assume complete control over LAVA. This transition will also result in the shares being delisted from Nasdaq, symbolizing a significant shift in the operational landscape for both companies.
Expert Advisors Behind the Deal
In executing this substantial acquisition, XOMA Royalty received legal guidance from Gibson, Dunn & Crutcher LLP and Loyens & Loeff N.V., alongside financial advisory from Leerink Partners for LAVA. Cooley LLP and NautaDutilh N.V. also provided crucial legal support.
XOMA Royalty: Innovating in Biotechnology
XOMA Royalty is recognized as a leading royalty aggregator within the biotechnology sector. The company plays a vital role in facilitating funding for biotechnology firms that are dedicated to advancing human health. By acquiring future economic benefits from both pre-commercial and commercial therapeutic candidates, XOMA supports sellers in advancing drug innovations without diluting their equity. Their portfolio boasts a range of valuable assets, ensuring a promising avenue for growth and investment.
Frequently Asked Questions
What does the acquisition of LAVA Therapeutics entail?
XOMA Royalty has acquired all outstanding common shares of LAVA Therapeutics, providing shareholders with both cash payments and a contingent value right for future earnings.
How will LAVA shareholders benefit from the CVR?
The CVR allows LAVA shareholders to receive a portion of future proceeds from the company's partnered assets, potentially increasing their total compensation.
Who advised XOMA Royalty during this transaction?
XOMA Royalty was represented by several legal and financial advisors, including Gibson, Dunn & Crutcher LLP and Loyens & Loeff N.V.
Why is XOMA Royalty's acquisition significant?
This acquisition strengthens XOMA’s portfolio and its strategic partnerships with major pharmaceutical companies, enhancing future growth potential.
What is XOMA Royalty's business model?
XOMA Royalty focuses on acquiring future economic rights linked to biotech products in development, offering funding solutions that do not dilute ownership for biotech firms.
